Cited by 1,110Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Open access

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A.B., Yeh, Matthew M., Johnson, Casey D., Van Rooyen, Derrick M., Haczeyni, Fahrettin, Teoh, Narci C.-H., Savard, Christopher, Ioannou, George N., Masters, Seth L., Schroder, Kate, Cooper, Matthew A., Feldstein, Ariel E., Farrell, Geoffrey C.·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2017.01.022PMC PMC6536116

Open this paper in CoChat — free account

Abstract

Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.01.022

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Inflammasomes
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Self-citation
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citation
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Self-citation
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940

Flagged first, then by citations

Show all 49 references

Sorted by citations

Items 301–400 of 999

Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19
Saeedi‐Boroujeni, A., Mahmoudian‐Sani, M., Nashibi, R., Houshmandfar, S., Gandomkari, S. T., & Khodadadi, A. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1925293 · Cited by 46
CBD Alleviates Liver Injuries in Alcoholics With High-Fat High-Cholesterol Diet Through Regulating NLRP3 Inflammasome–Pyroptosis Pathway
Jiang, X., Gu, Y., Huang, Y., Zhou, Y., Pang, N., Luo, J., Tang, Z., Zhang, Z., & Yang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724747 · Cited by 45
The critical role of short-chain fatty acids in health and disease: A subtle focus on cardiovascular disease-NLRP3 inflammasome-angiogenesis axis
Juan, Y., Chen, Y., & Xu, M. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109013 · Cited by 47
NLRP3 Inflammasome and Pyroptosis in Liver Pathophysiology: The Emerging Relevance of Nrf2 Inducers
Hurtado‐Navarro, L., Angosto-Bazarra, D., Pelegrín, P., Baroja‐Mazo, A., & Cuevas, S. (2022) · Antioxidants · doi:10.3390/antiox11050870 · Cited by 48
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 49
Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation
Dwivedi, D. K., & Jena, G. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1540-2 · Cited by 48
Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
Hundertmark, J., Krenkel, O., & Tacke, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02418 · Cited by 46
Oscillating lncRNA Platr4 regulates NLRP3 inflammasome to ameliorate nonalcoholic steatohepatitis in mice
Lin, Y., Wang, S., Gao, L., Zhou, Z., Yang, Z., Lin, J., Ren, S., Xing, H., & Wu, B. (2020) · Theranostics · doi:10.7150/thno.50281 · Cited by 45
Targeting fatty acid metabolism for fibrotic disorders
Hwang, S., & Chung, K. W. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01352-4 · Cited by 47
TGF-β activates NLRP3 inflammasome by an autocrine production of TGF-β in LX-2 human hepatic stellate cells
Kang, H., Seo, E., Oh, Y. S., & Jun, H. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04369-5 · Cited by 49
NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners
Leu, S., Tsang, Y.-L., Ho, L., Yang, C.-C., Shao, A., Chang, C.-Y., Lin, H.-K., Tsai, P.-J., Sung, J., & Tsai, Y.-S. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0184 · Cited by 46
The great potential of flavonoids as candidate drugs for NAFLD
Li, L., Qin, Y., Xin, X., Wang, S., Liu, Z., & Feng, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114991 · Cited by 47
Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Hamamah, S., Iatcu, O. C., & Covașă, M. (2024) · Nutrients · doi:10.3390/nu17010143 · Cited by 52
A critical role for the NLRP3 inflammasome in NASH
Thomas, H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.21 · Cited by 44
Involvement of HO-1 and Autophagy in the Protective Effect of Magnolol in Hepatic Steatosis-Induced NLRP3 Inflammasome Activation In Vivo and In Vitro
Kuo, N.-C., Huang, S.-Y., Yang, C., Shen, H., & Lee, Y. (2020) · Antioxidants · doi:10.3390/antiox9100924 · Cited by 44
Current and Potential Therapies Targeting Inflammation in NASH
Albhaisi, S. A. M., & Noureddin, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.767314 · Cited by 43
Runx2 activates hepatic stellate cells to promote liver fibrosis via transcriptionally regulating Itgav expression
Zhong, L., Zhao, J., Huang, L., Liu, Y., Pang, X., Zhan, K., Li, S., Xue, Q., Pan, X., & Deng, L. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1316 · Cited by 43
Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response
Mohamed, I., Li, L., Ismael, S., Ishrat, T., & El‐Remessy, A. B. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.1979 · Cited by 47
Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality
Yi, X., Ren, M., Yang, J., Cai, C., Cheng, W., Zhou, X., Lu, D., & Ji, F. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1003755 · Cited by 46
NLRP3 activation in neutrophils induces lethal autoinflammation, liver inflammation, and fibrosis
Kaufmann, B. K., Leszczynska, A., Reca, A., Booshehri, L. M., Onyuru, J., Tan, Z., Wree, A., Friess, H., Hartmann, D., Papouchado, B. G., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154446 · Cited by 44
Self-citation
Targeting TLRs and the inflammasome in systemic sclerosis
Henderson, J., Bhattacharyya, S., Varga, J., & O’Reilly, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.003 · Cited by 45
Role of NLRP3 inflammasome in liver disease
Mamun, A. A., Akter, A., Hossain, S., Sarker, T., Safa, S. A., Mustafa, Q. G., Muhammad, S. A., & Munir, F. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12918 · Cited by 43
Signaling Nodes Associated with Endoplasmic Reticulum Stress during NAFLD Progression
Koo, J. H., & Han, C. Y. (2021) · Biomolecules · doi:10.3390/biom11020242 · Cited by 43
Lycopene prevents non-alcoholic fatty liver disease through regulating hepatic NF-κB/NLRP3 inflammasome pathway and intestinal microbiota in mice fed with high-fat and high-fructose diet
Gao, X., Zhao, X., Liu, M., Zhao, H., & Sun, Y. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1120254 · Cited by 44
Roles of immune dysregulation in MASLD
Dong, T., Li, J., Liu, Y., Zhou, S., Wei, X., Hua, H., Tang, K., Zhang, X., Wang, Y., Wu, Z. F., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116069 · Cited by 43
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD
Zhang, L., Shi, Y., Liang, B., & Li, X. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000434 · Cited by 49
Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
Su, Q., Kuang, W., Hao, W., Liang, J., Wu, L., Tang, C., Wang, Y., & Liu, T. (2021) · Mediators of Inflammation · doi:10.1155/2021/8086253 · Cited by 44
Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases
Chen, Y., Yuan, S., Cao, Y., Kong, G., Jiang, F., Li, Y., Wang, Q., Tang, M., Zhang, Q., Wang, Q., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3206982 · Cited by 43
Sphingosine 1-Phosphate Receptor 4 Promotes Nonalcoholic Steatohepatitis by Activating NLRP3 Inflammasome
Hong, C. H., Ko, M. S., Kim, J. H., Cho, H.-K., Lee, C., Yoon, J. E., Yun, J.-Y., Baek, I., Jang, J. E., Lee, S. E., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.002 · Cited by 45
Clostridium septicum α-toxin activates the NLRP3 inflammasome by engaging GPI-anchored proteins
Jing, W., Pilato, J. L., Kay, C., Feng, S., Tuipulotu, D. E., Mathur, A., Shen, C. X., Ngo, C., Zhao, A., Miosge, L. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm1803 · Cited by 42
Self-citation
Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome
Wu, C., Bian, Y., Lu, B., Wang, D., Azami, N. L. B., Wei, G., Ma, F., & Sun, M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03495-4 · Cited by 43
Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH
Bala, S., Ganz, M., Babuta, M., Zhuang, Y., Csák, T., Calenda, C. D., & Szabó, G. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00626-1 · Cited by 41
Interleukin-18 in metabolism: From mice physiology to human diseases
Somm, E., & Jornayvaz, F. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.971745 · Cited by 44
Programmed cell death and lipid metabolism of macrophages in NAFLD
Xiao, Z., Liu, M., Yang, F., Liu, G., Liu, J., Zhao, W., Ma, S., & Duan, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118449 · Cited by 42
Kefir microbial composition is a deciding factor in the physiological impact of kefir in a mouse model of obesity
Bourrie, B. C. T., Ju, T., Fouhse, J. M., Forgie, A. J., Sergi, C. M., Cotter, P. D., & Willing, B. P. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520002743 · Cited by 43
The Role of the Interplay Between Autophagy and NLRP3 Inflammasome in Metabolic Disorders
Lv, S., Wang, H., & Li, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.634118 · Cited by 42
Caspase-11–Mediated Hepatocytic Pyroptosis Promotes the Progression of Nonalcoholic Steatohepatitis
Zhu, Y., Zhao, H., Lu, J. L., Lin, K., Ni, J., Wu, G., & Tang, H. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.04.009 · Cited by 40
Huangqin decoction mitigates hepatic inflammation in high-fat diet-challenged rats by inhibiting TLR4/NF-κB/NLRP3 pathway
Yan, B., Wang, Y., Wang, W., Ding, X., Wei, B., Liu, S., Fu, T., Chen, L., Zhang, J.-Z., Liu, J., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115999 · Cited by 40
Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice
Lu, Z., Liu, L., Zhao, S., Zhao, J., Li, S., & Li, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-34654-2 · Cited by 40
Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis
Li, Z., Chen, Y., Jiang, X., Lu, P., Wang, C., Li, Z., Yu, X., Yang, Z., Ma, S., Du, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00894 · Cited by 42
Salvianolic Acid B Alleviates Liver Injury by Regulating Lactate-Mediated Histone Lactylation in Macrophages
Hu, S., Yang, Z., Li, L., Yan, Q.-W., Hu, Y., Zhou, F., Tan, Y., & Pei, G. (2024) · Molecules · doi:10.3390/molecules29010236 · Cited by 40
Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways
Yong, Q., Huang, C., Chen, B., An, J., Zheng, Y., Zhao, L., Peng, C., & Liu, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116952 · Cited by 40
Evidence against a role for NLRP3-driven islet inflammation in db/db mice
Kammoun, H. L., Allen, T. L., Henstridge, D. C., Barre, S., Coll, R. C., Lancaster, G. I., Cron, L., Reibe, S., Chan, J. Y., Bensellam, M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.001 · Cited by 45
Self-citation
Deletion of NLRX1 increases fatty acid metabolism and prevents diet-induced hepatic steatosis and metabolic syndrome
Kors, L., Rampanelli, E., Stokman, G., Butter, L. M., Held, N. M., Claessen, N., Larsen, P. W. B., Verheij, J., Zuurbier, C. J., Liebisch, G., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.003 · Cited by 40
Tangshen Formula Alleviates Hepatic Steatosis by Inducing Autophagy Through the AMPK/SIRT1 Pathway
Wang, Y., Zhao, H., Li, X., Li, N., Wang, Q., Liu, Y., Liang, Q., Shao, Z., Zhang, N., Zhao, T., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00494 · Cited by 41
P7C3‐A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP‐activated protein kinase/CREB regulated transcription coactivator 2 pathway
Hua, X., Sun, D., Zhang, W., Fu, J., Tong, J., Sun, S., Zeng, F., Ouyang, S., Zhang, G., Wang, S., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15008 · Cited by 41
Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway
Zhang, Z., Zhou, H., Zhou, X., Sun, J., Liang, X., Lv, Y., Bai, L., Zhang, J., Gong, P., Liu, T., et al. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003001 · Cited by 41
AICAR, an AMP-Activated Protein Kinase Activator, Ameliorates Acute Pancreatitis-Associated Liver Injury Partially Through Nrf2-Mediated Antioxidant Effects and Inhibition of NLRP3 Inflammasome Activation
Kong, L., Zhang, H., Lu, C., Shi, K., Huang, H., Zheng, Y., Wang, Y., Wang, D., Wang, H., & Huang, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724514 · Cited by 40
Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study
Ali, F. E. M., Ibrahim, I. M., Ghogar, O. M., Abd‐alhameed, E. K., Althagafy, H. S., & Hassanein, E. H. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.1026 · Cited by 41
Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution
Yu, W., Zhang, Y., Sun, L., Huang, W., Li, X., Xia, N. L., Chen, X., Wikana, L. P., Xiao, Y., Chen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155911 · Cited by 43
A comparative review of intelectins
Chen, L., Li, J., & Yang, G. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12882 · Cited by 41
Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation
Farruggio, S., Cocomazzi, G., Marotta, P., Romito, R., Surico, D., Calamita, G., Bellan, M., Pirisi, M., & Grossini, E. (2020) · Cellular Physiology and Biochemistry · doi:10.33594/000000227 · Cited by 39
NLRP3 Inflammasome Blockade Reduces Cocaine-Induced Microglial Activation and Neuroinflammation
Chivero, E. T., Thangaraj, A., Tripathi, A., Periyasamy, P., Guo, M., & Buch, S. J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02184-x · Cited by 38
MSC-derived sEV-loaded hyaluronan hydrogel promotes scarless skin healing by immunomodulation in a large skin wound model
Yang, S., Jiang, H., Qian, M., Ji, G., Wei, Y., He, J., Tian, H., & Zhao, Q. (2022) · Biomedical Materials · doi:10.1088/1748-605x/ac68bc · Cited by 39
The discovery of NLRP3 and its function in cryopyrin‐associated periodic syndromes and innate immunity
Putnam, C. D., Broderick, L., & Hoffman, H. M. (2023) · Immunological Reviews · doi:10.1111/imr.13292 · Cited by 42
Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 41
Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?
Grunhut, J., Wang, W., Aykut, B., Gakhal, I., Torres-Hernandez, A., & Miller, G. (2018) · EMJ Hepatology · doi:10.33590/emjhepatol/10312252 · Cited by 38
Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death
Matsuoka, T., Yoshimatsu, G., Sakata, N., Kawakami, R., Tanaka, T., Yamada, T., Yoshida, Y., Hasegawa, S., & Kodama, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74786-3 · Cited by 38
Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro
Hwangbo, H., Kim, M. Y., Ji, S. Y., Kim, S. Y., Lee, H., Kim, G., Park, C., Keum, Y., Hong, S. H., Cheong, J., et al. (2020) · Antioxidants · doi:10.3390/antiox9111040 · Cited by 38
Cytokines and Their Genetic Polymorphisms Related to Periodontal Disease
Kozak, M., Dąbrowska‐Żamojcin, E., Mazurek−Mochol, M., & Pawlik, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124045 · Cited by 42
Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease
Liedtke, C., Nevzorova, Y. A., Luedde, T., Zimmermann, H. W., Kroy, D. C., Strnad, P., Berres, M., Bernhagen, J., Tacke, F., Nattermann, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.814496 · Cited by 43
Self-citation
Deoxycholic Acid Promotes Pyroptosis in Free Fatty Acid-Induced Steatotic Hepatocytes by Inhibiting PINK1-Mediated Mitophagy
Gao, X., Ruan, Y., Zhu, X., Lin, X., Yan, X., Li, X., Mai, M., & Guo, H. (2021) · Inflammation · doi:10.1007/s10753-021-01573-1 · Cited by 37
Efferocytosis in multisystem diseases (Review)
Zhang, Y., Wang, Y., Ding, J., & Liu, P. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12529 · Cited by 38
Novel insights into NOD-like receptors in renal diseases
Jin, J., Zhou, T.-J., Ren, G., Cai, L., & Meng, X. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00886-7 · Cited by 37
Inhibition of macrophages inflammasome activation via autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis
He, M., Chu, T., Wang, Z., Feng, Y., Shi, R., He, M., Feng, S., Lin, L., Cai, C., Fang, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147379 · Cited by 38
Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Yan, M., Man, S., Ma, L., Guo, L., Huang, L., & Gao, W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0315 · Cited by 39
Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity
Bertinaria, M., Gastaldi, S., Marini, E., & Giorgis, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.013 · Cited by 38
NLRP3 inflammasome in rosmarinic acid-afforded attenuation of acute kidney injury in mice
Akhter, J., Khan, J., Baghel, M., Beg, M. M. A., Goswami, P., Afjal, M. A., Ahmad, S., Habib, H., Najmi, A. K., & Raisuddin, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-04785-z · Cited by 37
The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
Xiang, H., Sun, D., Liu, X., She, Z., & Chen, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.812610 · Cited by 37
NLRP3 inflammasome in digestive diseases: From mechanism to therapy
Qiang, R., Li, Y., Dai, X.-C., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978190 · Cited by 39
Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH
Li, H., Cao, Z., Wang, L., Li, J., Cheng, X., Tang, Y., Xing, M., & Yao, P. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109217 · Cited by 36
The Potential of NLRP3 Inflammasome as a Therapeutic Target in Neurological Diseases
He, W., Hu, Z., Zhong, Y., Wu, C., & Li, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03229-7 · Cited by 38
NLRP3 Inflammasome Involvement in Heart, Liver, and Lung Diseases—A Lesson from Cytokine Storm Syndrome
Napodano, C., Carnazzo, V., Basile, V., Pocino, K., Stefanile, A., Gallucci, S., Natali, P., Basile, U., & Marino, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316556 · Cited by 38
The role of thyroid-stimulating hormone in regulating lipid metabolism: Implications for body–brain communication
Wang, X., Zhen, W., Liu, Y., Wu, C., Jiang, J., Hashimoto, K., & Zhou, X. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106658 · Cited by 41
Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms
Zhou, L., Lu, Y., Qiu, X., Chen, Z., Tang, Y., Meng, Z., Yan, C., Du, H., Li, S., & Lin, J. D. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115310 · Cited by 41
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 45
Mechanical stress overload promotes NF-κB/NLRP3-mediated osteoarthritis synovitis and fibrosis through Piezo1
Yu, L., Tian, D., Su, Z., Li, Z., Jie, L., Guo, S., Zhu, W., Zhang, L., & Wang, P. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111786 · Cited by 36
The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets
Weber, A. N. R., McManus, R. M., Hornung, V., Geyer, M., Kuemmerle-Deschner, J. B., & Latz, E. (2025) · Nature Immunology · doi:10.1038/s41590-025-02230-7 · Cited by 46
Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High‐Fat Diet: Possible Role of the NLRP3 Inflammasome
Fantauzzi, C. B., Menini, S., Iacobini, C., Rossi, C., Santini, E., Solini, A., & Pugliese, G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8962458 · Cited by 36
Pathogenesis of and major animal models used for nonalcoholic fatty liver disease
Jiang, M., Wu, N., Chen, X., Wang, W., Chu, Y., Liu, H., Li, W., Chen, D., Li, X., & Xu, B. (2019) · Journal of International Medical Research · doi:10.1177/0300060519833527 · Cited by 36
Carbamazepine promotes specific stimuli-induced NLRP3 inflammasome activation and causes idiosyncratic liver injury in mice
Wang, Z., Xu, G., Zhan, X., Liu, Y., Gao, Y., Chen, N., Guo, Y., Li, R., He, T., Song, X., et al. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02606-3 · Cited by 36
The P2X7 Receptor and NLRP3 Axis in Non-Alcoholic Fatty Liver Disease: A Brief Review
Rossato, M., Vincenzo, A. D., Pagano, C., Hadi, H. E., & Vettor, R. (2020) · Cells · doi:10.3390/cells9041047 · Cited by 36
The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia
Urwanisch, L., Luciano, M., & Horejs‐Hoeck, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031271 · Cited by 37
Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3
Xia, Y., Wang, P., Yan, N., Gonzalez, F. J., & Yan, T. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03243-w · Cited by 38
Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update
Elpek, G. Ö. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i19.4890 · Cited by 37
Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice
Zhang, Y., Wen, J., Liu, D., Qiu, Z., Zhu, Q., Li, R., & Zhang, Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119778 · Cited by 36
Activation of the NLRP3 Inflammasome Increases the IL-1β Level and Decreases GLUT4 Translocation in Skeletal Muscle during Insulin Resistance
Américo-Da-Silva, L., Aguilera, J., Quinteros-Waltemath, O., Sánchez-Aguilera, P., Russell‐Guzmán, J., Cadagan, C., Meneses‐Valdés, R., Sánchez, G., Estrada, M., Jorquera, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910212 · Cited by 39
Association Between the Children's Dietary Inflammatory Index (C-DII) and Markers of Inflammation and Oxidative Stress Among Children and Adolescents: NHANES 2015-2018
Zhang, C., Ren, W., Li, M., Wang, W., Sun, C. C., Liu, L., Fang, Y., Liu, L., Yang, X., Zhang, X., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.894966 · Cited by 36
Chlorogenic acid ameliorated non-alcoholic steatohepatitis via alleviating hepatic inflammation initiated by LPS/TLR4/MyD88 signaling pathway
Gu, X.-N., Wei, M., Hu, F., Ouyang, H., Huang, Z., Lü, B., & Ji, L. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110461 · Cited by 35
Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023
Duan, M., Sun, L., He, X., Wang, Z., Hou, Y., & Zhao, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115750 · Cited by 36
Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL
Ding, L., Huwyler, F., Long, F., Wu, Y., Binz, J., Wernlé, K., Pfister, M., Klug, M., Baláž, M., Ukropcová, B., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01386-y · Cited by 37
Galectin-12 in Cellular Differentiation, Apoptosis and Polarization
Wan, L., Yang, R., & Liu, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010176 · Cited by 35
Kefir in the Prevention and Treatment of Obesity and Metabolic Disorders
Bourrie, B. C. T., Richard, C., & Willing, B. P. (2020) · Current Nutrition Reports · doi:10.1007/s13668-020-00315-3 · Cited by 35
Long-Term Aspartame Administration Leads to Fibrosis, Inflammasome Activation, and Gluconeogenesis Impairment in the Liver of Mice
Finamor, I., Bressan, C. A., Torres-Cuevas, I., Rius‐Pérez, S., da Veiga, M. L., da Rocha, M. I. D. U. M., Pavanato, M. A., & Pérez, S. (2021) · Biology · doi:10.3390/biology10020082 · Cited by 42
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities
Zhang, C., Hu, Y., Sun, P., Hua, L., Liang, S., Ou, Y., Wu, D., Wu, X., Chen, H. H., Hao, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113417 · Cited by 34
Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome
Kim, H., Choi, Y. J., Kim, S. K., Kim, H., Jun, D. W., Yoon, K., Kim, N., Hwang, J., Kim, Y. M., Lim, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02345-1 · Cited by 35
Anti-neuroinflammatory effects of novel 5,6-dihydrobenzo[h]quinazolin-2-amine derivatives in lipopolysaccharide-stimulated BV2 microglial cells
Zhang, X.-F., Luan, M.-Z., Yan, W.-B., Zhao, F.-L., Hou, Y., Hou, G., & Meng, Q. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114322 · Cited by 35
Emerging Role of NLRP3 Inflammasome and Pyroptosis in Liver Transplantation
Lucas‐Ruiz, F., Peñín‐Franch, A., Pons, J. A., Ramírez, P., Pelegrı́n, P., Cuevas, S., & Baroja‐Mazo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214396 · Cited by 35
Aqueous extract of Polygala japonica Houtt. ameliorated nonalcoholic steatohepatitis in mice through restoring the gut microbiota disorders and affecting the metabolites in feces and liver
Liao, J., Cao, Y., Zhao, J., Yu, B., Wang, Y., Li, W., Li, H., Lv, S., Wen, W., Cui, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154937 · Cited by 34
Gut microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease
Yu, T., Luo, L., Xue, J., Tang, W., Wu, X., & Fan, Y. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102458 · Cited by 41

Authors: Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
Affiliations: Australian National University (AU)
University of California San Diego (US)
The University of Queensland (AU)
University of Washington (US)
Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author: Farrell, Geoffrey C.
ORCID: Mridha, Auvro R.
Wree, Alexander
Robertson, Avril A.B.
Yeh, Matthew M.
Johnson, Casey D.
Haczeyni, Fahrettin
Savard, Christopher
Ioannou, George N.
Masters, Seth L.
Schroder, Kate
Cooper, Matthew A.
Feldstein, Ariel E.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1037-1046
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2017.01.022
PMC: PMC6536116
OpenAlex: W2585046292
Cited by: 1,110
References: 49
Citations by year: 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
FWCI: 57.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks